These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

197 related items for PubMed ID: 1311035

  • 1. Evaluation of liver tumors using fluorine-18-fluorodeoxyglucose PET: characterization of tumor and assessment of effect of treatment.
    Okazumi S, Isono K, Enomoto K, Kikuchi T, Ozaki M, Yamamoto H, Hayashi H, Asano T, Ryu M.
    J Nucl Med; 1992 Mar; 33(3):333-9. PubMed ID: 1311035
    [Abstract] [Full Text] [Related]

  • 2. In vivo assessment of glucose metabolism in hepatocellular carcinoma with FDG-PET.
    Torizuka T, Tamaki N, Inokuma T, Magata Y, Sasayama S, Yonekura Y, Tanaka A, Yamaoka Y, Yamamoto K, Konishi J.
    J Nucl Med; 1995 Oct; 36(10):1811-7. PubMed ID: 7562048
    [Abstract] [Full Text] [Related]

  • 3. [Can fluorodeoxyglucose-positron emission tomography evaluate the functional differentiation of hepatocellular carcinoma].
    Enomoto K, Fukunaga T, Okazumi S, Asano T, Kikuchi T, Yamamoto H, Nagashima T, Isono K, Itoh H, Imazeki K.
    Kaku Igaku; 1991 Nov; 28(11):1353-6. PubMed ID: 1663176
    [Abstract] [Full Text] [Related]

  • 4. Value of fluorine-18-FDG-PET to monitor hepatocellular carcinoma after interventional therapy.
    Torizuka T, Tamaki N, Inokuma T, Magata Y, Yonekura Y, Tanaka A, Yamaoka Y, Yamamoto K, Konishi J.
    J Nucl Med; 1994 Dec; 35(12):1965-9. PubMed ID: 7989978
    [Abstract] [Full Text] [Related]

  • 5. Evaluation of esophageal cancers using fluorine-18-fluorodeoxyglucose PET.
    Fukunaga T, Okazumi S, Koide Y, Isono K, Imazeki K.
    J Nucl Med; 1998 Jun; 39(6):1002-7. PubMed ID: 9627333
    [Abstract] [Full Text] [Related]

  • 6. [Evaluation of the effect of treatment in patients with liver tumors using 18F-fluorodeoxyglucose PET].
    Okazumi S, Enomoto K, Ozaki M, Yamamoto H, Yoshida M, Abe Y, Takayama W, Yamada S, Isono K, Imazeki K.
    Kaku Igaku; 1989 Jun; 26(6):793-7. PubMed ID: 2796006
    [Abstract] [Full Text] [Related]

  • 7. Clinical implication of glucose transport and metabolism evaluated by 18F-FDG PET in hepatocellular carcinoma.
    Paudyal B, Paudyal P, Oriuchi N, Tsushima Y, Nakajima T, Endo K.
    Int J Oncol; 2008 Nov; 33(5):1047-54. PubMed ID: 18949368
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Evaluation of experimental liver tumors using fluorine-18-2-fluoro-2-deoxy-D-glucose PET.
    Oya N, Nagata Y, Ishigaki T, Abe M, Tamaki N, Magata Y, Konishi J.
    J Nucl Med; 1993 Dec; 34(12):2124-9. PubMed ID: 8254399
    [Abstract] [Full Text] [Related]

  • 10. Increased accumulation of 2-deoxy-2-[18F]Fluoro-D-glucose in liver metastases from colon carcinoma.
    Yonekura Y, Benua RS, Brill AB, Som P, Yeh SD, Kemeny NE, Fowler JS, MacGregor RR, Stamm R, Christman DR, Wolf AP.
    J Nucl Med; 1982 Dec; 23(12):1133-7. PubMed ID: 6982967
    [Abstract] [Full Text] [Related]

  • 11. Noninvasive monitoring of tumor metabolism using fluorodeoxyglucose and positron emission tomography in colorectal cancer liver metastases: correlation with tumor response to fluorouracil.
    Findlay M, Young H, Cunningham D, Iveson A, Cronin B, Hickish T, Pratt B, Husband J, Flower M, Ott R.
    J Clin Oncol; 1996 Mar; 14(3):700-8. PubMed ID: 8622014
    [Abstract] [Full Text] [Related]

  • 12. [Analysis of glucose metabolism in patients with esophageal cancer by PET: estimation of hexokinase activity in the tumor and usefulness for clinical assessment using 18F-fluorodeoxyglucose].
    Fukunaga T, Enomoto K, Okazumi S, Kikuchi T, Yamamoto H, Koide Y, Isono K.
    Nihon Geka Gakkai Zasshi; 1994 May; 95(5):317-25. PubMed ID: 8007937
    [Abstract] [Full Text] [Related]

  • 13. Evaluation of the effect of glucose ingestion and kinetic model configurations of FDG in the normal liver.
    Choi Y, Hawkins RA, Huang SC, Brunken RC, Hoh CK, Messa C, Nitzsche EU, Phelps ME, Schelbert HR.
    J Nucl Med; 1994 May; 35(5):818-23. PubMed ID: 8176464
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. A modeling method to improve quantitation of fluorodeoxyglucose uptake in heterogeneous tumor tissue.
    Wu HM, Huang SC, Choi Y, Hoh CK, Hawkins RA.
    J Nucl Med; 1995 Feb; 36(2):297-306. PubMed ID: 7830134
    [Abstract] [Full Text] [Related]

  • 18. Determination of 18F-fluoro-2-deoxy-D-glucose rate constants in the anesthetized baboon brain with dynamic positron tomography.
    Miyazawa H, Osmont A, Petit-Taboué MC, Tillet I, Travère JM, Young AR, Barré L, MacKenzie ET, Baron JC.
    J Neurosci Methods; 1993 Dec; 50(3):263-72. PubMed ID: 8152238
    [Abstract] [Full Text] [Related]

  • 19. Diminished glucose transport and phosphorylation in Alzheimer's disease determined by dynamic FDG-PET.
    Piert M, Koeppe RA, Giordani B, Berent S, Kuhl DE.
    J Nucl Med; 1996 Feb; 37(2):201-8. PubMed ID: 8667045
    [Abstract] [Full Text] [Related]

  • 20. Determination of regional rate constants from dynamic FDG-PET studies in Parkinson's disease.
    Piert M, Koeppe RA, Giordani B, Minoshima S, Kuhl DE.
    J Nucl Med; 1996 Jul; 37(7):1115-22. PubMed ID: 8965180
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.